Sustained Remission with Mogamulizumab in Peripheral T Cell Lymphoma with Aberrant CD20 Expression: Case Report and Literature Review

Full-Text HTML XML Download Download as PDF (Size:1959KB) PP. 179-187
DOI: 10.4236/jct.2018.93018    410 Downloads   809 Views
Author(s)
Kentaro Fukushima1, Hiroshi Sata1, Masami Imakita2, Takahiro Karasuno1

Affiliation(s)

1Department of Hematology, Rinku General Medical Center, Izumisano, Osaka, Japan.
2Department of Pathology, Rinku General Medical Center, Izumisano, Osaka, Japan.

ABSTRACT

A 82-year-old man presented with an enlarged multiple superficial lymph nodes. The histological diagnosis of lymph node was peripheral T cell lymphoma, not otherwise specified (PTCL-NOS), with an aberrant expression of CD20. Generally, PTCL lacks B cell antigen such as CD19 or CD20, however, rare cases have been reported in the literature that showed PTCL patients expressing the B cell antigens. It is considered that the prognosis of CD20 positive PTCL is poor, however, standard therapy has not been established. He was treated with eight cycles of CHOP regimen, but the enlargement of a part of lymph nodes still remained. Recently, it is reported that C-C Chemokine receptor type 4 (CCR4) is known to be expressed about 50% case of PTCL and CCR4 target therapy is effective. Our case was positive for CCR4 so mogamulizumab (anti-CCR4 antibody) was administered. Consequently, dramatic response was obtained and its combination of these therapy resulted in complete remission for 24 months. This is the first case of sustained remission by administration of mogamulizumab against CCR4/CD20 double positive PTCL. This strategy may be benefit to obtain the good prognosis.

KEYWORDS

Peripheral T Cell Lymphoma, CD20, PTCL-NOS, Aberrant Expression, Mogamulizumab

Cite this paper

Fukushima, K. , Sata, H. , Imakita, M. and Karasuno, T. (2018) Sustained Remission with Mogamulizumab in Peripheral T Cell Lymphoma with Aberrant CD20 Expression: Case Report and Literature Review. Journal of Cancer Therapy, 9, 179-187. doi: 10.4236/jct.2018.93018.
JCT Subscription
E-Mail Alert
JCT Most popular papers
Publication Ethics & OA Statement
JCT News
Frequently Asked Questions
Recommend to Peers
Recommend to Library
Contact Us

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.